VIDEO: Vedolizumab may benefit Crohn’s patients who fail anti-TNF therapy

Vedolizumab was not superior to placebo for inducing remission at 6 weeks in patients with Crohn’s disease who failed to respond to anti–tumor necrosis factor therapy, according to findings from the...